Optimizing differentiated treatment models for people living with HIV in urban Zimbabwe: Findings from a mixed methods study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 14 08 2019
accepted: 09 01 2020
entrez: 29 1 2020
pubmed: 29 1 2020
medline: 18 4 2020
Statut: epublish

Résumé

Zimbabwe is scaling up HIV differentiated service delivery (DSD) to improve treatment outcomes and health system efficiencies. Shifting stable patients into less-intensive DSD models is a high priority in order to accommodate the large numbers of newly-diagnosed people living with HIV (PLHIV) needing treatment and to provide healthcare workers with the time and space needed to treat people with advanced HIV disease. DSD is also seen as a way to improve service quality and enhance retention in care. National guidelines support five differentiated antiretroviral treatment models (DART) for stable HIV-positive adults, but little is known about patient preferences, a critical element needed to guide DART scale-up and ensure person-centered care. We designed a mixed-methods study to explore treatment preferences of PLHIV in urban Zimbabwe. The study was conducted in Harare, and included 35 health care worker (HCW) key informant interviews (KII); 8 focus group discussions (FGD) with 54 PLHIV; a discrete choice experiment (DCE) in which 500 adult DART-eligible PLHIV selected their preferences for health facility (HF) vs. community location, individual vs. group meetings, provider cadre and attitude, clinic operation times, visit frequency, visit duration and cost to patient; and a survey with the 500 DCE participants exploring DART knowledge and preferences. Patient preferences were consistent in the FGDs, DCE and survey. Participants strongly preferred respectful HCWs, HF-based services, individual DART models, and less costly services. Patients also preferred less frequent visits and shorter wait times. They were indifferent to variations in HCW cadre and distances from home to HF. These preferences were mostly homogenous, with only minor differences between male vs. female and older vs. younger patients. HCWs in the KII correctly characterized facility-based individual models as the one most favored by patients; HCWs also preferred this model, which they felt decongested HFs and reduced their workload. DART-eligible PLHIV in Harare found it relatively easy to access HFs, and preferred attributes associated with facility-based individual models. Prioritizing these for scale-up in urban areas may be the most efficient way to sustain positive patient outcomes and increase health system performance.

Identifiants

pubmed: 31990930
doi: 10.1371/journal.pone.0228148
pii: PONE-D-19-22981
pmc: PMC6986745
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

figshare
['10.6084/m9.figshare.11594859.v1']

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0228148

Subventions

Organisme : PEPFAR
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Policy Plan. 2009 Mar;24(2):151-8
pubmed: 19112071
Nurs Res. 2008 May-Jun;57(3):220-4
pubmed: 18496108
South Afr J HIV Med. 2018 Aug 09;19(1):721
pubmed: 30214827
PLoS Med. 2018 Aug 13;15(8):e1002636
pubmed: 30102693
BMJ Glob Health. 2018 Oct 25;3(5):e001007
pubmed: 30483408
Curr Opin HIV AIDS. 2019 Jan;14(1):60-65
pubmed: 30394947
BMJ Qual Saf. 2019 Apr;28(4):257-259
pubmed: 30591539
J Public Health (Oxf). 2017 Sep 1;39(3):e63-e72
pubmed: 27412176
AIDS. 2016 Sep 10;30(14):2145-8
pubmed: 27367489
Am J Public Health. 2009 Sep;99(9):1666-72
pubmed: 19608959
J Assoc Nurses AIDS Care. 2016 Jul-Aug;27(4):419-29
pubmed: 26995502
PLoS One. 2016 Aug 23;11(8):e0160764
pubmed: 27551785
Health Technol Assess. 2001;5(5):1-186
pubmed: 11262422
J Int AIDS Soc. 2016 Feb 10;19(1):20171
pubmed: 26869359
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546
pubmed: 31021988
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
PLoS Med. 2017 Nov 7;14(11):e1002421
pubmed: 29112691

Auteurs

Miriam Rabkin (M)

ICAP at Columbia University, New York, New York, United States of America.
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, United States of America.

Michael Strauss (M)

Health Economics and HIV/AIDS Research Division (HEARD), University of KwaZulu Natal, Durban, South Africa.

Joanne E Mantell (JE)

Department of Psychiatry, Division of Gender, Sexuality and Health, Columbia University, New York, New York, United States of America.
The New York State Psychiatric Institute, New York, New York, United States of America.

Munyaradzi Mapingure (M)

ICAP at Columbia University, Harare, Zimbabwe.

Tsitsi B Masvawure (TB)

Department of Sociology and Anthropology, College of the Holy Cross, Worcester, Massachusetts, United States of America.

Matthew R Lamb (MR)

ICAP at Columbia University, New York, New York, United States of America.
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, United States of America.

Jennifer M Zech (JM)

ICAP at Columbia University, New York, New York, United States of America.

Godfrey Musuka (G)

ICAP at Columbia University, Harare, Zimbabwe.

Innocent Chingombe (I)

ICAP at Columbia University, Harare, Zimbabwe.

Martin Msukwa (M)

ICAP at Columbia University, Pretoria, South Africa.

Rodrigo Boccanera (R)

Health Resources and Services Administration (HRSA), Bethesda, Maryland, United States of America.

Clorata Gwanzura (C)

Ministry of Health and Child Care, HIV/AIDS and STIs Unit, Harare, Zimbabwe.

Gavin George (G)

Health Economics and HIV/AIDS Research Division (HEARD), University of KwaZulu Natal, Durban, South Africa.

Tsitsi Apollo (T)

Ministry of Health and Child Care, HIV/AIDS and STIs Unit, Harare, Zimbabwe.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH